Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiovascular Risk Factors in Rheumatoid Arthritis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2025 Feb 17

PMID 39962010

Authors

A N Saidi

W B Theel

B Burggraaf

A J van der Lelij

D E Grobbee

J D van Zeben

E van der Zwan-van Beek

S P Rauh

M Castro Cabezas

Affiliations

Soon will be listed here.

Abstract

Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease linked with metabolic dysfunction-associated steatotic liver disease (MASLD), which may increase cardiovascular (CV) risk. This study explores the association between liver fibrosis, assessed by the Fibrosis-4 (FIB-4) index, and CV risk factors in RA patients.

Methods: Cross-sectional data from the Franciscus Rheumatoid Arthritis and Cardiovascular Intervention Study (FRANCIS), a randomized, cardiovascular single center, intervention study involving RA patients without cardiovascular disease (CVD) or type 2 diabetes (T2DM), were analyzed. Liver fibrosis was assessed using FIB-4, with a cut-off point of ≥ 1.3 to define high fibrosis risk, and its relationship with CV risk factors, medication use, and subclinical atherosclerosis, measured by carotid intima-media thickness (cIMT), was evaluated.

Results: Among 326 patients (68.4% female, age 53 ± 11 years, BMI 26.5 ± 4.5 kg/m), those with high FIB-4 (n = 49) had higher cIMT (p = 0.002), apolipoprotein B48 (p = 0.04), systolic blood pressure (p = 0.007), alkaline phosphatase (p = 0.002), and anti-CCP levels (p = 0.02). High FIB-4 was associated with lower leukocyte count and complement component 3. Statin use was linked to higher FIB-4 (OR = 4.49, p = 0.014), while hydroxychloroquine use was associated with lower FIB-4 (OR = 0.11, p = 0.004). Disease activity scores did not differ between low and high FIB-4 groups.

Conclusions: Elevated FIB-4 in RA patients is associated with increased cIMT, higher blood pressure, and elevated atherogenic remnants. Incorporating FIB-4 measurements into routine clinical care for RA populations could effectively identify individuals at the highest CV risk, enabling the implementation of more intensive CV risk management strategies. Key Points • RA patients with liver fibrosis have higher cIMT, indicating greater risk of atherosclerosis. • RA patients with liver fibrosis show accumulation of circulating atherogenic chylomicron remnants, contributing to atherogenesis. • HCQ may provide a protective effect against liver fibrosis in RA patients.

References

Di Matteo A, Bathon J, Emery P . Rheumatoid arthritis. Lancet. 2024; 402(10416):2019-2033. DOI: 10.1016/S0140-6736(23)01525-8. View

Conforti A, Di Cola I, Pavlych V, Ruscitti P, Berardicurti O, Ursini F . Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2020; 20(2):102735. DOI: 10.1016/j.autrev.2020.102735. View

Figus F, Piga M, Azzolin I, McConnell R, Iagnocco A . Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev. 2021; 20(4):102776. DOI: 10.1016/j.autrev.2021.102776. View

Radovanovic-Dinic B, Tesic-Rajkovic S, Zivkovic V, Grgov S . Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int. 2018; 38(5):715-724. DOI: 10.1007/s00296-018-4021-5. View

Craig E, Cappelli L . Gastrointestinal and Hepatic Disease in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2017; 44(1):89-111. PMC: 5726432. DOI: 10.1016/j.rdc.2017.09.005. View

Sellami M, Saidane O, Mahmoud I, Ben Tekaya A, Tekaya R, Abdelmoula L . Etiological Features of Liver Involvement in Rheumatoid Arthritis. Curr Rheumatol Rev. 2019; 16(4):332-336. DOI: 10.2174/1573397115666191007121605. View

Zamani M, Alizadeh-Tabari S, Chitkara P, Singh S, Loomba R . Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023; 21(11):2789-2796. PMC: 10792512. DOI: 10.1016/j.cgh.2023.02.021. View

Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

Avina-Zubieta J, Choi H, Sadatsafavi M, Etminan M, Esdaile J, Lacaille D . Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59(12):1690-7. DOI: 10.1002/art.24092. View

10.

Sakthiswary R, Chan G, Koh E, Leong K, Thong B . Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. ScientificWorldJournal. 2014; 2014:823763. PMC: 4058155. DOI: 10.1155/2014/823763. View

11.

Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y . Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One. 2018; 13(8):e0203084. PMC: 6108522. DOI: 10.1371/journal.pone.0203084. View

12.

Hernandez N, Bessone F . Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. J Clin Transl Hepatol. 2022; 10(3):486-495. PMC: 9240255. DOI: 10.14218/JCTH.2021.00243. View

13.

Dijkshoorn B, Raadsen R, Nurmohamed M . Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. J Clin Med. 2022; 11(10). PMC: 9142998. DOI: 10.3390/jcm11102704. View

14.

Semb A, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S . Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020; 16(7):361-379. DOI: 10.1038/s41584-020-0428-y. View

15.

Barbarroja N, Ruiz-Ponce M, Cuesta-Lopez L, Perez-Sanchez C, Lopez-Pedrera C, Arias-de la Rosa I . Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. Front Immunol. 2022; 13:997270. PMC: 9539434. DOI: 10.3389/fimmu.2022.997270. View

16.

Nurmohamed M, Heslinga M, Kitas G . Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015; 11(12):693-704. DOI: 10.1038/nrrheum.2015.112. View

17.

Bonek K, Gluszko P . Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach. Reumatologia. 2016; 54(3):128-35. PMC: 4967980. DOI: 10.5114/reum.2016.61214. View

18.

Chung C, Oeser A, Solus J, Avalos I, Gebretsadik T, Shintani A . Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2007; 196(2):756-63. DOI: 10.1016/j.atherosclerosis.2007.01.004. View

19.

Mulumba C, Lebughe P, Mbuyi-Muamba J, Makulo J, Lepira F, Mukaya J . Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa. BMC Rheumatol. 2019; 3:37. PMC: 6732832. DOI: 10.1186/s41927-019-0085-4. View

20.

Rajabzadeh F, Akhlaghipour I, Moosavi S, Shad A, Babazadeh Baghan A, Shariati-Sarabi Z . Comparison of the intima-media thickness of the common carotid artery in patients with rheumatoid arthritis: A single-center cross-sectional case-control study, and a brief review of the literature. Health Sci Rep. 2023; 6(11):e1718. PMC: 10654376. DOI: 10.1002/hsr2.1718. View